Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - methylphenidate hydrochloride, quantity: 40 mg - capsule, hard - excipient ingredients: gelatin; strong ammonia solution; purified talc; potassium hydroxide; triethyl citrate; ammonio methacrylate copolymer; iron oxide red; propylene glycol; methacrylic acid copolymer; iron oxide yellow; titanium dioxide; povidone; shellac; sucrose; maize starch - rubifen la modified release capsules are indicated for the treatment of attention-deficit hyperactivity disorder (adhd).,adhd adhd was previously known as attention-deficit disorder. other terms used to describe this behavioural syndrome include: minimal brain dysfunction in children, hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction and psycho-organic syndrome of children.,rubifen la modified release capsules are indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis.,special diagnostic considerations for adhd in children the aetiology of this syndrome is unknown and there is no single diagnostic test. adequate diagnosis requires the use, not only of medical, but also of psychological, educational and social resources. characteristics commonly reported include: chronic history of short attention span, distractibility, emotional lability, impulsivity, moderate to severe hyperactivity, minor neurological signs and an abnormal eeg. learning may or may not be impaired. the diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics.,drug treatment is not indicated for all children with this syndrome. stimulants are not intended for use in children who exhibit symptoms secondary to environmental factors (e.g. child abuse in particular) or primary psychiatric disorders. appropriate educational placement is essential and psychosocial intervention is generally necessary. when remedial measures alone are insufficient, the decision to prescribe stimulant medicine will depend upon the physician's assessment of the chronicity and severity of the child's symptoms.,continuation of treatment in adolescent and special diagnostic considerations for adhd in adults there is limited information to guide clinicians about how long older adolescents should continue to receive treatment with drugs for attention deficit hyperactivity disorder (adhd). the decision should be based on the extent to which symptoms of adhd and social functioning have improved to a point that medication is no longer needed. if older adolescents have been largely symptom-free for a year and are functioning well, a trial without medication is warranted. this should be undertaken at times of low stress such as during holidays or in a period when a school routine is well established.,adhd needs to be considered in adults who present with longstanding symptoms suggestive of adhd (inattention, impulsivity, disorganisation) that appear to have started in childhood and are persisting into adult life. further, people with personality disorder and/or problems with drug use accompanied by a significant level of impulsivity and inattention should be referred for evaluation by a psychiatrist with the training and skills required to assess and treat adhd. this expertise is necessary due to the overlap of adhd symptoms with anxiety, mood and personality disorders.

India - English - Central Drugs Standard Control Organization

la serena - pantoprazole,domperidone - tab - 40,10;mg - 10

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

f. hoffmann-la roche ltd. - levodopa, benserazide (benserazide hydrochloride) - capsules hard - 100mg+25mg

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - morphine sulfate pentahydrate 100mg - modified release tablet - 100 mg - active: morphine sulfate pentahydrate 100mg excipient: hyetellose hypromellose magnesium stearate opadry grey oy-8238 povidone purified talc - arrow-morphine la tablets are indicated for the prolonged relief of opioid responsive severe and intractable pain in adults. use in non-malignant pain: the use of arrow-morphine la tablets for the treatment of pain which is not due to malignancy should be restricted to situations where: · all other conservative methods of analgesia have been tried and have failed; · the pain is having a significant impact on the patient's quality of life; · there is no psychological contraindication, drug seeking behaviour or history of drug abuse.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - morphine sulfate pentahydrate 10mg - modified release tablet - 10 mg - active: morphine sulfate pentahydrate 10mg excipient: hyetellose hypromellose lactose monohydrate magnesium stearate opadry buff oy-3607 povidone purified talc - arrow-morphine la tablets are indicated for the prolonged relief of opioid responsive severe and intractable pain in adults. use in non-malignant pain: the use of arrow-morphine la tablets for the treatment of pain which is not due to malignancy should be restricted to situations where: · all other conservative methods of analgesia have been tried and have failed; · the pain is having a significant impact on the patient's quality of life; · there is no psychological contraindication, drug seeking behaviour or history of drug abuse.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - morphine sulfate pentahydrate 30mg - modified release tablet - 30 mg - active: morphine sulfate pentahydrate 30mg excipient: hyetellose hypromellose lactose monohydrate magnesium stearate opadry violet 0y-6708 povidone purified talc - arrow-morphine la tablets are indicated for the prolonged relief of opioid responsive severe and intractable pain in adults. use in non-malignant pain: the use of arrow-morphine la tablets for the treatment of pain which is not due to malignancy should be restricted to situations where: · all other conservative methods of analgesia have been tried and have failed; · the pain is having a significant impact on the patient's quality of life; · there is no psychological contraindication, drug seeking behaviour or history of drug abuse.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - morphine sulfate pentahydrate 60mg - modified release tablet - 60 mg - active: morphine sulfate pentahydrate 60mg excipient: hyetellose hypromellose lactose monohydrate magnesium stearate opadry orange oy-3533 povidone purified talc - arrow-morphine la tablets are indicated for the prolonged relief of opioid responsive severe and intractable pain in adults. use in non-malignant pain: the use of arrow-morphine la tablets for the treatment of pain which is not due to malignancy should be restricted to situations where: · all other conservative methods of analgesia have been tried and have failed; · the pain is having a significant impact on the patient's quality of life; · there is no psychological contraindication, drug seeking behaviour or history of drug abuse.

Ireland - English - HPRA (Health Products Regulatory Authority)

abbott laboratories ireland ltd - clarithromycin - modified-release tablets - 500 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - methylphenidate hydrochloride - prolonged release capsules - 30 milligram - centrally acting sympathomimetics

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - methylphenidate hydrochloride - prolonged release capsules - 20 milligram - centrally acting sympathomimetics